Cytofluorescence evidence of adriamycin in liver.
Fluorescence study was carried out in Sprague-Dawley rats injected intravenously with the anti-cancer drug adriamycin (ADR) at a dose of 15 mg/kg to determine the site of its localization in liver. Significant fluorescence emission of ADR nuclear-binding appeared in the liver shortly after the drug administration. The occurrence of the nuclear fluorescence in our material was explained by the binding of ADR to DNA. The cytoplasmic drug loading of liver cells might reflect their role in the drug metabolism.